Sales Battle Card: Nilo Therapeutics $101M Series A

🚀 Battle Card: Nilo Therapeutics

• Kim Seth, CEO 📧 kim@nilotx.com

• This Nilo Therapeutics sales trigger means they’re flush with capital and gearing up to scale R&D infrastructure. → Source

• Limited preclinical assay capacity for neural circuit-based immunotherapies

• Urgent need to fast-track preclinical-to-clinical transition

• Primary: Preclinical CRO services → rapid assay deployment (capitalize on the Nilo Therapeutics sales trigger)

• Expansion: Clinical trial management platform → streamlined multi-site trials

• HQ: New York, NY, US

• Employees: ≈ 60

• Rev: ≈ $0 (pre-revenue)

• Website: nilotx.com

🤼 Competitive Intel

• Charles River Laboratories — Preclinical CRO
• Unique edge: deep immunology assay portfolio
• Evaluated by VP R&D for preclinical expertise

• Labcorp — Clinical development services
• Unique edge: end-to-end trial management
• Evaluated by Dir. Clinical Ops for global trial reach

• IQVIA — Data analytics & clinical trials
• Unique edge: integrated data analytics platform
• Evaluated by VP Data Science for predictive insights

• Thermo Fisher Scientific — Lab equipment & consumables
• Unique edge: comprehensive assay kits
• Evaluated by Lab Managers for throughput

• Parexel — Full-service CRO
• Unique edge: regulatory strategy expertise
• Evaluated by CEO/CFO for compliance assurance

✅ Do-Now Checklist

Next Step

🧠 Copy My Prompt for Personalized Cold Outreach

────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY   = ❑<your company>❑
OFFER_BRIEF   = ❑Rapid preclinical CRO services❑
PROOF_METRIC  = ❑50% faster assay results❑
CTA_STYLE     = ❑quick_call❑
TONE          = ❑friendly❑

────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME        = Kim
COMPANY     = Nilo Therapeutics
DEPT        = R&D
SIZE        = 60
BOTTLENECK  = limited preclinical assay capacity
EVENT       = $101M Series A financing
DETAIL      = launch & $101M Series A financing
PAIN        = urgent need to fast-track preclinical-to-clinical transition
SRC         = https://vcnewsdaily.com/nilo-therapeutics/venture-capital-funding/lcclqqdvkh
SIM_CO      = Cerevance
WIN_METRIC  = 50% faster assay results
NEXT_SIZE   = 100
EMP_EST     = ≈ 60
REV_EST     = ≈ $0

────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.

Validate any ≈ guesses via SRC.

EMAIL  (keep breaks):
Subject: 60-person R&D

Kim—noticed your R&D team is ≈ 60.

That’s when limited preclinical assay capacity slows growth.

We helped Cerevance fix this with Rapid preclinical CRO services.

Result: 50% faster assay results.  
Quick call?

PS—next bottleneck hits ≈ 100.

DM ≤45 words, TONE:
Saw your post about launch & $101M Series A financing — urgent need to fast-track preclinical-to-clinical transition.  
Rapid preclinical CRO services. 50% faster assay results.  
Quick chat?